Condition
Recessive Dystrophic Epidermolysis Bullosa clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Recessive Dystrophic Epidermolysis Bullosa clinical trials that are recruiting, at sites in 2 countries (most in United States (4), Canada (1)). By phase: Phase 1/2 (2), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest Recessive Dystrophic Epidermolysis Bullosa clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Long-Term Safety Follow-Up After pz-cel for RDEB | — | Palo Alto, California and 3 other locations | Recruiting | Jul 14, 2026 |
| Gene-modified autologous skin graft (GMEB-SASS) for RDEB | Phase 1/2 | Toronto, Ontario | Recruiting | Sep 25, 2025 |
| KB803 eye drops versus placebo for people with dystrophic epidermolysis bullosa | Phase 3 | Rancho Santa Margarita, California and 4 other locations | Recruiting | Jun 12, 2025 |
| Using IV immunoglobulin to lower collagen VII antibodies in dystrophic epidermolysis bullosa | Phase 1/2 | Redwood City, California | Recruiting | Feb 19, 2025 |
| Long-term follow-up for gene therapy in skin conditions | — | Rancho Santa Margarita, California and 2 other locations | Recruiting | Jun 8, 2021 |
All recruiting trials (5)
-
Long-Term Safety Follow-Up After pz-cel for RDEB
This study follows people with RDEB who were treated with pz-cel to see how safe it is over up to 15 years and whether their wounds stay healed.
-
Gene-modified autologous skin graft (GMEB-SASS) for RDEB
This trial will try a gene-modified skin graft grown from a patient's own cells to help wounds heal in people with recessive dystrophic epidermolysis bullosa (RDEB).
-
KB803 eye drops versus placebo for people with dystrophic epidermolysis bullosa
This trial tests whether KB803 eye drops, given three times a week, can reduce recurrent corneal abrasions in children and adults with dystrophic epidermolysis bullosa.
-
Using IV immunoglobulin to lower collagen VII antibodies in dystrophic epidermolysis bullosa
This trial tests whether IV immunoglobulin given to people with recessive dystrophic epidermolysis bullosa who are on VYJUVEK helps wounds heal faster and lowers collagen VII and HSV‑1 antibody levels.
-
Long-term follow-up for gene therapy in skin conditions
This study is checking the long-term safety of a gene therapy for people with a skin condition called dystrophic epidermolysis bullosa who have already received the treatment.
Related topics
Quick answers
How many Recessive Dystrophic Epidermolysis Bullosa clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (4 trials), Canada (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.